There is much global research interest surrounding the use of cell-free DNA (cfDNA) for
liquid biopsies. cfDNA-based non-invasive prenatal testing for foetal chromosomal …

Liquid biopsy recently became a very promising diagnostic method that has several
advantages over conventional invasive methods. Liquid biopsy may serve as a source of …

Cell-free circulating DNA (cfDNA) in plasma has gained global interest as a diagnostic
material for noninvasive prenatal testing and cancer diagnosis, or the so-called “liquid …

A liquid biopsy is a minimally invasive or non-invasive method to analyze a range of tumor
material in blood or other body fluids, including circulating tumor cells (CTCs), cell-free DNA …

Hepatocellular carcinoma (HCC), with its high incidence and mortality rate, is one of the
most common malignant tumors. Despite recent development of a diagnostic and treatment …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

The initial discovery of cell-free DNA (cfDNA) in 1948 by Mandel and Metais has led to
numerous investigations evaluating the role of cfDNA in various disease states. cfDNA has …

Liquid biopsy is a broad term that refers to the testing of body fluids for biomarkers that
correlate with a pathological condition. While a variety of body-fluid components (eg …

Since its discovery in human blood plasma about 70 years ago, circulating cell-free DNA
(cfDNA) has become an attractive subject of research as noninvasive disease biomarker …

Cell-free DNA (cfDNA) in bodily fluids has rapidly transformed the development of
noninvasive prenatal testing, cancer liquid biopsy, and transplantation monitoring. Plasma …